Welcome to our dedicated page for Inmune Bio SEC filings (Ticker: INMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to INmune Bio Inc. (NASDAQ: INMB) SEC filings, giving investors and researchers insight into the company’s clinical-stage biotechnology activities focused on the innate immune system. INmune Bio’s common stock is registered on The Nasdaq Stock Market LLC under the symbol INMB, and the company files periodic and current reports, proxy statements and other documents with the U.S. Securities and Exchange Commission.
Through Forms 10-K and 10-Q, users can review detailed discussions of INmune Bio’s DN-TNF platform (including XPro™/XPro1595), the CORDStrom™ human umbilical cord-derived mesenchymal stromal cell platform, and the INKmune® natural killer cell priming platform, along with risk factors, research and development expenses, and liquidity information. Current reports on Form 8-K document material events such as clinical trial updates, conference presentations, registered direct offerings, special stockholder meetings, option repricing approvals, and management or governance changes.
Definitive proxy statements on Schedule DEF 14A describe matters submitted to stockholders, including special meetings and proposals related to equity incentive plans. For capital markets activity, filings may include shelf registration statements, prospectus supplements and related exhibits describing registered direct offerings and placement agency agreements. Where applicable, Form 4 and other beneficial ownership reports provide information on insider transactions in INMB common stock.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping users interpret complex disclosures about clinical programs, financing arrangements and corporate actions. Real-time updates from EDGAR ensure that new INmune Bio filings are available as soon as they are posted, while AI tools highlight notable changes across annual reports, quarterly reports and 8-Ks so that readers can quickly focus on items most relevant to the DN-TNF, CORDStrom™ and INKmune® platforms.
Inmune Bio, Inc. (INMB) director reprices stock options following shareholder approval. On November 18, 2025, the company’s stockholders approved a one-time repricing of certain outstanding stock options granted under Inmune Bio’s 2017, 2019 and 2021 stock incentive plans. The repricing reduced the per-share exercise price of each affected option to $1.50, which was the closing price of Inmune Bio common stock on The Nasdaq Capital Market on the repricing date. The table shows prior options with exercise prices such as $7.80, $3.91, $24.82, $17.49, and others being replaced with new options at $1.50 for the same share amounts, including grants of 108,000 and 35,000 shares. All other terms of these options, including vesting schedules and expiration dates, remain unchanged and continue to depend on the director’s ongoing service.
Inmune Bio, Inc. (INMB) reported a change in the stock options held by its interim CFO, Cory Randall Ellspermann. On November 18, 2025, shareholders approved a one-time repricing of certain outstanding options granted under the company’s 2017, 2019 and 2021 stock incentive plans. The repricing reduced the exercise price of each affected option to $1.50 per share, which was the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date.
The Form 4 shows cancellations of existing stock options with higher exercise prices and the grant of replacement options at the new $1.50 exercise price for the same numbers of underlying shares and original expiration dates. All other terms of these options, including vesting schedules and overall terms, remain unchanged and continue to depend on the executive’s ongoing service with the company.
Inmune Bio, Inc. (INMB) director Marcia Allen reported a repricing of her stock options, following stockholder approval effective November 18, 2025. Certain existing options granted under the company’s 2017, 2019 and 2021 stock incentive plans had their exercise price reduced to $1.50 per share, matching the Nasdaq closing price of Inmune Bio’s common stock on the repricing date. The filing shows prior options with higher exercise prices, including awards at $3.91, $7.92, $9.74, $17.49, $24.82 and $5.05, being adjusted so that the same numbers of underlying shares remain, but at the new exercise price. All other terms of these options, such as vesting schedules and expiration dates, remain unchanged, and the awards continue to be tied to Allen’s ongoing service with the company.
INmune Bio Inc. reported that stockholders approved a one-time repricing of certain outstanding stock options covering up to 5,511,000 shares under its equity incentive plans. Effective November 18, 2025, the exercise price of these options for eligible employees and directors was reduced to $1.50 per share, matching the Nasdaq closing price that day, while all other option terms remain unchanged.
At the special meeting, 26,585,258 shares were entitled to vote, with 10,193,242 shares represented, establishing a quorum. The option repricing proposal passed with 7,144,433 votes for, 2,926,973 against, and 121,836 abstentions. INmune Bio also announced in a press release that it will deliver two presentations at the 18th Clinical Trials on Alzheimer’s Disease conference in San Diego from December 1–4, 2025.
INmune Bio (INMB) furnished an Investor Presentation under Regulation FD. The company reported via an 8-K that a slide deck intended for periodic presentations was made available as Exhibit 99.1. The disclosure is provided under Item 7.01, which is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference.
The filing also lists Exhibit 104 for the cover page interactive data file embedded within the Inline XBRL document.
INmune Bio Inc. filed a current report stating that on October 30, 2025 it announced financial results for the quarter ended September 30, 2025 and provided a business update. The company released these details through a press release, which is attached as Exhibit 99.1.
The report clarifies that the press release and related information are being furnished rather than filed under securities laws, limiting their use for certain legal liability purposes unless specifically incorporated by reference into other regulatory documents.
INmune Bio (INMB) reported third‑quarter 2025 results with a net loss of $6,472,000 and other income of $961,000, driven largely by interest income and a $0.6M vendor settlement gain. Cash and cash equivalents were $27,734,000 at September 30, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern based on projected operating needs versus available liquidity.
Operating expenses fell year over year as research and development declined to $4,887,000 on trial completion and staff reductions, while general and administrative was $2,546,000. For the nine months, the company recorded a $16,514,000 impairment to XPro in‑process R&D after its Phase 2 did not meet primary and key secondary endpoints, and it halted immediate plans to develop XPro while seeking a partner. The company advanced CORDStrom for RDEB, with FDA Rare Pediatric Disease and Orphan Drug Designations, and intends to pursue a BLA. Shares outstanding were 26,585,258 as of October 30, 2025.
INmune Bio (INMB) will host a conference call on October 30, 2025 at 4:30 p.m. Eastern Time to discuss results for its third quarter ended September 30, 2025 and provide a corporate update. The company attached a related press release as Exhibit 99.1.
INmune Bio (INMB) called a virtual special meeting on November 18, 2025 to seek stockholder approval to reprice certain outstanding stock options. The plan would reset the exercise price of eligible options granted between January 1, 2018 and January 22, 2025 to the closing price of the Company’s common stock on the meeting date, with all other terms (vesting and expiration) unchanged.
The Board cites retention and alignment as key reasons. As of September 30, 2025, the stock closed at $2.07 per share, leaving 100% of options under the 2017, 2019 and 2021 plans underwater. Group-level eligibility includes 2,647,000 options for current executive officers as a group, 1,356,000 for non‑employee directors as a group, and 1,508,000 for non‑executive employees as a group. A separate proposal would allow adjournment to solicit additional proxies if needed. Stockholders of record at close of business on September 30, 2025 (26,585,258 shares outstanding) may vote.
INmune Bio reported that CEO David Moss will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC. The event takes place at the Hard Rock Hotel in New York City on October 22–23, 2025.
The company furnished a related press release dated October 14, 2025 as Exhibit 99.1 under Item 8.01.